ST. HELIER, Jersey (AP) — ST. HELIER, Jersey (AP) — NovoCure Ltd. (NVCR) on Thursday reported a loss of $65.9 million in its fourth quarter.
The St. Helier, Jersey-based company said it had a loss of 61 cents per share.
The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share.
The oncology drug developer posted revenue of $161.3 million in the period, which met Street forecasts.
For the year, the company reported a loss of $168.6 million, or $1.56 per share. Revenue was reported as $605.2 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NVCR at https://www.zacks.com/ap/NVCR
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。